Tag Archives: Soliris

September, 2018

25 September
Alexion’s Soliris Demonstrates Positive Results in Phase 3 Study in Patients with Neuromyelitis Optica Spectrum Disorder

BOSTON–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced positive topline results from the Phase 3 PREVENT study of Soliris® (eculizumab) in patients with anti-aquaporin-4 (AQP4) auto antibody-positive neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, devastating, complement-mediated disorder of the central nervous system characterized by relapses. Each relapse results in stepwise …
Share

25 October
FDA Approves Alexion’s Soliris for Treatment of Generalized Myasthenia Gravis

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved Soliris® (eculizumab) as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive. In the Phase 3 REGAIN study and its ongoing open-label extension study, Soliris …
Share

14 September
Alexion’s Soliris Demonstrates Positive Results in Phase 3 Open-Label Extension Study in Refractory Generalized Myasthenia Gravis

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris® (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The new results …
Share

22 December
Alexion’s Soliris Fails to Meet Primary Endpoint in Mid-Stage Study in Kidney Transplant Patients

December 21, 2016 04:04 PM Eastern Standard Time NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today reported results from the PROTECT Study, a Phase 2/3 registration trial of eculizumab (Soliris®) for the prevention of delayed graft function (DGF) after kidney transplantation in adult recipients of a deceased donor kidney. …
Share

18 November
Alexion Announces that Data from Global aHUS Registry Shows Reduced Risk with Soliris

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new data from an analysis of patients enrolled in the Global atypical Hemolytic Uremic Syndrome (aHUS) Registry, demonstrating that initiation of Soliris® (eculizumab) prior to kidney transplant reduces the risk of dialysis post-transplant in patients with aHUS. Specifically, …
Share

6 May
Alexion Enhances its Rare Disease Business Acquiring Synageva for $8.4 Billion

Rare disease company Alexion Pharmaceuticals, Inc. agreed to acquire smaller rival Synageva BioPharma Corp for $8.4 billion in cash and stock, more than double its market value. The companies announced today that they have entered into a definitive agreement, under which Alexion will acquire Synageva for consideration for $115 in …
Share